Inari Medical (NARI) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Inari Medical (NASDAQ: NARI) recently:

• 1/8/2025 – Inari Medical had its “neutral” rating reaffirmed by analysts at BTIG Research.
• 1/7/2025 – Inari Medical had its price target raised by analysts at Piper Sandler from $52.00 to $80.00. They now have a “neutral” rating on the stock.
• 1/7/2025 – Inari Medical had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $80.00 price target on the stock, down previously from $81.00.
• 1/7/2025 – Inari Medical had its “market perform” rating reaffirmed by analysts at William Blair.
• 1/7/2025 – Inari Medical was downgraded by analysts at Baird R W from a “strong-buy” rating to a “hold” rating.
• 1/7/2025 – Inari Medical had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $80.00 price target on the stock, up previously from $74.00.
• 1/7/2025 – Inari Medical had its “equal weight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $80.00 price target on the stock, up previously from $65.00.
• 12/18/2024 – Inari Medical had its price target raised by analysts at Truist Financial Co. from $50.00 to $63.00. They now have a “hold” rating on the stock.
• 12/17/2024 – Inari Medical is now covered by analysts at Oppenheimer Holdings Inc.. They set an “outperform” rating and a $75.00 price target on the stock.

Inari Medical Trading Up 0.1 %

Inari Medical stock opened at $79.34 on Tuesday. The stock has a fifty day moving average price of $54.72 and a 200 day moving average price of $49.63. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.69. The firm has a market capitalization of $4.64 billion, a P/E ratio of -58.77 and a beta of 0.97.

Insider Transactions at Inari Medical

In related news, CEO Andrew Hykes sold 3,000 shares of the company’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. This represents a 0.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total value of $2,002,000.00. Following the completion of the sale, the director now directly owns 561,233 shares of the company’s stock, valued at $28,089,711.65. The trade was a 6.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 406,000 shares of company stock worth $22,621,870 in the last three months. Company insiders own 10.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC increased its holdings in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after acquiring an additional 473 shares during the last quarter. KBC Group NV lifted its position in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Inari Medical during the 2nd quarter valued at about $104,000. Finally, Quest Partners LLC boosted its position in shares of Inari Medical by 31,257.1% during the second quarter. Quest Partners LLC now owns 2,195 shares of the company’s stock worth $106,000 after buying an additional 2,188 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.